3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
2
Phase 3
1
Phase 2
1
Phase 1/2
1
Status
Recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Prostatic Neoplasms
12
Prostatic Neoplasms, Castration-Resistant
2
Neoplasm Metastasis
2
Urogenital Neoplasms
1
Urogenital Diseases
1
Thrombocytosis
1
Prostatic Diseases
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Metastatic Castration-resistant Prostate Neoplasms
1
Metastatic Castration-resistant Prostate Cancer
1
Male Urogenital Diseases
1
Lymphoma, Non-Hodgkin
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
1
Leukemia, Myeloid, Acute
1
Leukemia, Myeloid, Accelerated Phase
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hodgkin Disease
1
Hematologic Neoplasms
1
Healthy Volunteers
1
Interventions
enzalutamide
4
darolutamide
2
xentuzumab
1
olaparib
1
ipatasertib
1
ibrutinib
1
gallium 68 PSMA-11
1
atezolizumab
1
apalutamide
1
TVB-2640
1
Rosuvastatin Calcium
1
Pioglitazone
1
JNJ-64619178
1
JNJ-64264681
1
Docetaxel
1
(225)Ac-PSMA-617
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 1
×
Prostatic Neoplasms, Castration-Resistant
×
darolutamide
×
Clear all
NCT05997615
2026-04-20
AMX-500
Vir Biotechnology, Inc.
Phase 1
Recruiting
390 enrolled
NCT05519449
2026-01-20
ENGAGER-PSMA-01
Janux Therapeutics
Phase 1
Recruiting
272 enrolled